Latest News for LCTX
Lineage Cell Therapeutics NYSEAMERICAN: LCTX outlined progress across its cell-therapy pipeline during its second-quarter 2026 earnings call, highlighting preclinical advances in corneal disease, Type 1 diabetes and hearing loss programs while Roche and Genentech continue surgical-delivery optimization work for its lead OpRegen program.
Lineage Cell Therapeutics, Inc. (LCTX) Q2 2026 Earnings Call Transcript
Lineage Cell (LCTX) came out with a quarterly loss of $0.03 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.01 per share a year ago.
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Q2 2026 Earnings Release.
Lineage Cell Therapeutics NYSEAMERICAN: LCTX used a conference call to outline its manufacturing strategy and development plans for COR1, a wholly owned preclinical cell transplant program being developed as a potential treatment for corneal endothelial disease.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for LCTX.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.